Senators stuck to mostly familiar or expected subjects during their questioning of Robert Califf, nominated to be the next US Food and Drug Administration commissioner.
As in previous confirmation hearings, the most questions to Califf by members of the Senate Health, Education, Labor and Pensions Committee during the 14 December session dealt with drug development, according to a Pink Sheet analysis
More Coverage Of Califf’s Confirmation Hearing
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on HBW Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?